Whereas neuropsychological assessment is used for clinical diagnosis of AD and FTD-tau, the definitive diagnosis rests on the assessment of the distribution and severity of tau and amyloid-β deposition in the post mortem brain [2, 3]. This evidence concerns the gene MAPT and frontotemporal dementia.